CVRx Reports First Quarter 2023 Financial and Operating Results MINNEAPOLIS

CVRx Reports First Quarter 2023 Financial and

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc.

(NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing

innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for

the first quarter of 2023.

"I am thrilled with our first quarter performance, which demonstrated

solid execution on multiple fronts. We were able to share the preliminary data from BeAT-HF during the first quarter and grow our US heart

failure business. This is a testament to our team's ability to accelerate adoption of Barostim through the increased capabilities

of our commercial organization and our marketing and awareness efforts," said Nadim Yared, President and Chief Executive Officer

of CVRx. "As we look ahead to the rest of 2023, we are excited about the opportunities that lie ahead and confident that we will

bring relief to patients suffering from heart failure."

First Quarter 2023 Financial and Operating Results

Revenue was $8.0 million for the three months ended March 31,

2023, an increase of $3.9 million, or 96%, over the three months ended March 31, 2022.

Revenue generated in the U.S. was $6.9 million for the three months

ended March 31, 2023, an increase of $3.9 million, or 127%, over the three months ended March 31, 2022. HF revenue units in

the U.S. totaled 225 and 99 for the three months ended March 31, 2023 and 2022, respectively. HF revenue in the U.S. totaled $6.8

million and $2.9 million for the three months ended March 31, 2023 and 2022, respectively. The increases were primarily driven by

continued growth in the U.S. HF business as a result of the expansion into new sales territories, new accounts and increased physician

and patient awareness of Barostim.

As of March 31, 2023, the Company had a total of 122 active implanting

centers, as compared to 106 as of December 31, 2022. Active implanting centers are customers that have completed at least one commercial

HF implant in the last 12 months. The number of sales territories in the U.S. increased by three to a total of 29 during the three months

ended March 31, 2023.

Revenue generated in Europe was $1.0 million for the three months ended

March 31, 2023, an increase of $0.02 million, or 2%, over the three months ended March 31, 2022. Total revenue units in Europe

increased to 52 for the three months ended March 31, 2023 from 50 in the prior year period. The number of sales territories in Europe

remained consistent at six for the three months ended March 31, 2023.

Gross profit was $6.7 million for the three months ended March 31,

2023, an increase of $3.5 million, or 113%, over the three months ended March 31, 2022. Gross margin increased to 83% for the three

months ended March 31, 2023 compared to 77% for the three months ended March 31, 2022. Gross margin for the three months ended

March 31, 2023 improved due primarily to a decrease in the cost per unit driven by an increase in the production volume.

R&D expenses increased $1.2 million, or 51%, to $3.4 million for

the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This change was driven by a $0.5 million

increase in compensation expenses as a result of increased headcount, a $0.4 million increase in non-cash stock-based compensation expense

and a $0.4 million increase in consulting fees.

SG&A expenses increased $4.6 million, or 43%, to $15.4 million

for the three months ended March 31, 2023 compared to the three months ended March 31, 2022. This change was primarily driven

by a $2.6 million increase in compensation expenses, mainly as a result of increased headcount, a $0.8 million increase in travel expenses,

a $0.6 million increase in marketing and advertising expenses associated with the commercialization of Barostim in the U.S., and a $0.5

million increase in non-cash stock-based compensation expense.

Other income, net was $1.1 million for the three months ended March 31,

2023 compared to other expense, net of $57,000 for the three months ended March 31, 2022. The income in the first quarter of 2023

was primarily driven by interest income on our interest-bearing account.

Net loss was $11.4 million, or $0.55 per share, for the three months

ended March 31, 2023, compared to a net loss of $10.0 million, or $0.49 per share, for the three months ended March 31, 2022.

Net loss per share was based on 20,693,224 weighted average shares outstanding for the first quarter of 2023 and 20,453,341 weighted average

shares outstanding for the first quarter of 2022.

As of March 31, 2023, cash and cash equivalents were $103.3 million.

Net cash used in operating and investing activities was $10.5 million for the quarter ended March 31, 2023, compared to $10.9 million

for the quarter ended March 31, 2022.

For the full year of 2023, the Company expects:

For the second quarter of 2023, the Company expects to report total

revenue between $8.2 million and $8.8 million.

Webcast and Conference Call Information

The Company will host a conference call to review its results at 5:00

p.m. Eastern Time today. A live webcast of the investor conference call will be available online at the investor relations page of

the Company's website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers,

or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.

CVRx is a commercial-stage medical device company focused on developing,

manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the

first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is

an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate

the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to

the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation

and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension

in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking

statements, including statements regarding our future financial performance (including, specifically, our 2023 expected operating

and financial results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should,"

"expect," "plan," "anticipate," "could," "outlook," "guidance,"

"intend," "target," "project," "contemplate," "believe," "estimate,"

"predict," "potential" or "continue" or the negative of these terms or other similar expressions,

although not all forward-looking statements contain these words.

The forward-looking statements in this press release are only predictions

and are based largely on our current expectations and projections about future events and financial trends that we believe may affect

our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press

release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history

of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single

product, Barostim; our ability to establish and maintain sales and marketing capabilities; our ability to demonstrate to physicians and

patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim;

our competitors' success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise

more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers,

and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including

the outbreak of the novel strain of coronavirus, COVID-19; any failure of clinical studies for future indications to produce results necessary

to support regulatory clearance or approval in the U.S. or elsewhere; product liability claims; future lawsuits to protect or enforce

our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives

or recruit and hire new employees; and other important factors that could cause actual results, performance or achievements to differ

materially from those that are found in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for

the year ended December 31, 2022, as such factors may be updated from time to time in our other filings with the Securities and Exchange

Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained

herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Mark Klausner or Mike Vallie

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)